Findings

What do systematic reviews say?

8 questions · 8 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 37.5%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 4 · 50%Moderate 0 · 0%High 0 · 0%

Heparin vs placebo

Major bleeding events: unfractionated heparin · kidney transplant recipients

Heparin showed no clear difference in major bleeding events: unfractionated heparin compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing thrombosis in solid organ transplant recipients 2021 · Cochrane Headline outcomes only
RR 2.92 [0.89, 9.56]
3 studies · 155 participants
Low

Subcutaneous unfractionated heparin vs unfractionated heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (7 days ‐ 12 months) compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.91 [0.42, 1.97]
4 studies · 583 participants
Low

Unfractionated heparin vs low molecular weight heparin

Major bleeding · CRRT

Unfractionated heparin showed no clear difference in major bleeding compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
RR 0.58 [0.13, 2.58]
5 studies · 153 participants
Low

Subcutaneous unfractionated heparin vs low molecular weight heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes only
OR 0.72 [0.43, 1.2]
5 studies · 2300 participants
Low

Unfractionated heparin vs no thromboprophylaxis

Major bleeding · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs no pharmacological anticoagulation

Major bleeding · CRRT

It is very uncertain whether unfractionated heparin changes major bleeding compared with no pharmacological anticoagulation (very low certainty).

1 finding from 1 review

Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement… 2020 · Cochrane Headline outcomes only
RR 0.5 [0.05, 4.67]
1 study · 10 participants
Very low

Low molecular weight heparin vs unfractionated heparin

Major bleeding · adults with kidney failure treated with long‐term HD

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for people receiving long‐term haemodialysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs unfractionated heparin

Major bleeding · patients with cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found